Transdermal drug delivery by microneedles: does skin metabolism matter? by Barrak Al-Qallaf (7128776) et al.
 
 
 
This item was submitted to Loughborough’s Institutional Repository 
(https://dspace.lboro.ac.uk/) by the author and is made available under the 
following Creative Commons Licence conditions. 
 
 
 
 
 
For the full text of this licence, please go to: 
http://creativecommons.org/licenses/by-nc-nd/2.5/ 
 
INTERNATIONAL JOURNAL OF CHEMICAL
REACTOR ENGINEERING
Volume 7 2009 Article A69
Transdermal Drug Delivery by
Microneedles: Does Skin Metabolism
Matter?
Barrak Al-Qallaf∗ Daisuke Mori† Lola Olatunji‡
Diganta Bhusan Das∗∗ Zhanfeng Cui††
∗University of Oxford, b alqallaf@hotmail.com
†Biocom Systems Inc., daisuke.mori@biocom.co.jp
‡Loughborough University, b 118ers@hotmail.co.uk
∗∗Loughborough University, d.b.das@lboro.ac.uk
††University of Oxford, zhanfeng.cui@eng.ox.ac.uk
ISSN 1542-6580
Copyright c©2009 The Berkeley Electronic Press. All rights reserved.
Transdermal Drug Delivery by Microneedles: Does
Skin Metabolism Matter?
Barrak Al-Qallaf, Daisuke Mori, Lola Olatunji, Diganta Bhusan Das, and
Zhanfeng Cui
Abstract
Microneedle arrays have been shown to increase skin permeability for the
transdermal delivery of drugs with high molecular weights. Various theoretical
studies have been proposed to predict the drug transport behaviour after drug in-
jection using microneedles. However it is important for the optimal design of
microneedle systems to consider the effects of biological factors such as skin
metabolism and variations in pharmacokinetic parameters as well as to improve
the enhancement of skin permeability. A mathematical model for microneedle
systems is introduced and applied to simulate the verapamil transport with metabolism
in the skin. A comparative analysis for a transdermal delivery of verapamil from
microneedles is presented in this paper. The results indicate that the skin metabolism
does not markedly affect the skin permeation after verapamil injection using mi-
croneedles.
KEYWORDS:microneedles, transdermal drug delivery, pharmacokinetics, mod-
elling, skin metabolism, reaction
INTRODUCTION 
 
A number of mathematical frameworks have been developed for evaluating both 
the skin permeation and blood concentration of drug delivered using microneedle 
arrays (Al-Qallaf and Das, 2009a; Al-Qallaf and Das, 2009b, Davidson et al, 
2008; Al-Qallaf et al, 2007; Lv et al, 2006; McAllister et al, 2003). In most of 
these cases, the metabolism of the drug has not been considered. Consequently the 
skin permeation and blood concentration of the drug have been modelled 
assuming no drug metabolism in the viable skin. For example, we have previously 
evaluated the effects of volume of distribution (Vb) and elimination rate constant 
(Ke) on the fentanyl concentration in blood without considering the skin 
metabolism (Al-Qallaf et al, 2007; McAllister et al, 2003). Other general 
mathematical models for molecule transport across skin have also been proposed 
which have not included the influence of skin metabolism, see e.g., the reviews by 
Godin and Touitou (2007) and, Yamashita and Hashida (2003). Similarly, Simon 
et al (2006) proposed a mathematical model of iontophoretic transdermal drug 
delivery and assumed no drug metabolism in the viable skin. Although these 
modelling studies were useful, there are a number of situations where drug 
metabolism in skin during transdermal delivery in general, and microneedle 
arrays specifically, might be important. For example, Yamashita and Hashida 
(2003) argue that the skin metabolism may be an important factor for developing 
transdermal drug delivery approach. Indeed many studies considered the influence 
of drug metabolism in skin (Boderke et al, 200; Sugibayashi et al, 1999; Bando et 
al, 1997; Auton, 1993). However, these studies are insufficient in determining the 
implications of the skin metabolism for transdermal drug delivery using 
microneedles. This is obvious because the drugs are injected in the viable 
epidermis in this case instead of the top of the skin, and the influence of the path 
lengths for drug transport across skin on the kinetics of metabolism may be 
different.  This has been explained in more detail in the subsequent sections.  
The purpose of this paper is to develop a mathematical framework to 
examine the importance of considering skin metabolism for drug delivery using 
microneedle arrays. In particular, we are interested to determine the implications 
of verapamil delivery using microneedle arrays. Verapamil is used for many 
medical purposes such as preventing heart attack (Simonetti et al, 1986) lowering 
blood pressure (Trewet and Ernest, 2008), and stopping cluster headache attacks 
(Tobin and Flitman, 2008) and diarrhea due to microscopic colitis (Scheidler and 
Meiselman, 2001). The administration of verapamil is often done orally. However 
it has been shown that the bioavailability of verapamil may be reduced by 80-90% 
if the oral route is chosen (Choi et al, 2008, Michel et al, 2006). On the other 
hand, others argue that it can be delivered by transdermal route which seems to 
improve the bioavailability of verapamil (Shah et al, 1992a). Shah et al. (1992b) 
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concluded that not all the amount of delivered verapamil reached the blood 
circulation. One of the possible reasons to explain this effect was that the 
verapamil could be metabolized in the skin (Shah et al 1992b). Assuming that one 
wishes to adopt transdermal routes for delivery of verapamil, it is not certain what 
role the microneedle arrays could play for its delivery. To this end, one needs to 
determine the advantage of microneedles over a normal patch for verapamil 
delivery and determine the implications of verapamil metabolism in skin.  To 
analyse these issues, we have carried out simulations for both common 
transdermal patch and microneedle arrays in this paper.  
As mentioned previously, many theoretical models of transdermal drug 
delivery have been proposed to study the influence of skin metabolism. However, 
most of these models have studied the influence of skin metabolism for the full 
skin thickness (i.e., the stratum corneum and viable skin together). In fact, skin 
metabolism occurs primarily in the viable epidermis (Amsden and Goosen, 1995).   
In order to validate this fact we have carried out simulations of the common patch 
with two hypothetical cases. To make a logical comparison, the simulations of 
these two hypothetical cases have been carried out for the same transdermal drug 
delivery system (i.e., common patch) with the same input parameters. The first 
case represents the common patch on the top of the stratum corneum. The second 
case represents the common patch on the top of the viable epidermis. A 
comparison for these two hypothetical cases has been presented to show the 
influence of skin metabolism. Based on the result of this comparison, we have 
carried out another simulation for the microneedle arrays. The simulations of 
microneedles have been carried out by adopting a previous microneedle model 
(Davidson et al, 2008). In addition, several studies have been obtained by carrying 
out simulations using SKIN-CAD® (Kimura and Tojo, 2007; Tojo and Hikima, 
2007; Mori et al., 2003). However, to our best knowledge, skin metabolism has 
not been considered during the simulations carried out for these previous studies.  
In this work, a study of both skin permeation and verapamil concentration 
in blood have been carried out based on a diffusion model including a metabolic 
process.  Improving upon our previous work (Davidson et al, 2008; Al-Qallaf et 
al, 2007) we have introduced mono and bi-layer diffusion models with two 
compartment model to estimate verapamil concentration in blood when either 
applied as a patch or injected using microneedle. In all cases, the cumulative 
amounts of verapamil permeated per unit area of skin with and without skin 
metabolism have been numerically determined. Moreover, the distribution of 
verapamil across skin for the transdermal delivery using microneedles has been 
obtained. Therefore, the analysis of both verapamil permeation and the verapamil 
concentration in blood are thought to be useful. In particular, this is important to 
identify the impact of skin metabolism when applying the transdermal delivery of 
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verapamil using microneedles. In fact, this helps to clarify the argument about the 
assumption of neglecting skin metabolism in viable skin as discussed previously. 
 
MODELING STRATEGY 
 
A schematic diagram of the developed mathematical framework of transdermal 
delivery of verapamil for both the patch and microneedle arrays is illustrated in 
Figure 1. There are two main transdermal drug delivery systems in the figure: a 
transdermal patch containing verapamil at a homogeneous concentration (Shah et 
al, 1992c) and a microneedle array coated with verapamil solution (Davidson et 
al, 2008). Application of the transdermal patch is divided into two hypothetical 
cases that represent application on the top of either the stratum corneum or viable 
epidermis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Schematic diagram of transdermal drug delivery for both patch and microneedle arrays 
(adopted from Al-Qallaf et al.(2007)) 
 
 In the first case, verapamil penetrates the stratum corneum, partitions 
towards and penetrates the viable epidermis and then enters the blood circulation 
(Tojo, 1987). In the second case, verapamil diffuses across the viable epidermis 
and then is absorbed by the blood circulation. Although this is a hypothetical case 
designed purely for the purpose of this study, the result obtained for this case is 
expected to be useful since it has been shown that drug may be metabolized in the 
viable epidermis (Amsden and Goosen, 1995). In the figure, Sa is the surface area 
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of both the transdermal patch and microneedle arrays, L is the penetration depth 
of microneedles, Heff is the effective skin thickness (i.e., effective path length of 
molecules in tissue) that verapamil molecules can pass in the tissue from 
microneedle which depends on the needle geometry (Davidson et al, 2008). 
Verapamil is defined to get absorbed into two compartments (i.e., blood 
compartment and tissue compartment) with first order elimination kinetics (Tojo, 
1987).  
 
Model assumptions 
 
The mathematical framework in this work is based on the following assumptions: 
(1) The skin metabolism is defined to follow first order kinetics (Lee et al, 
1996; Sato and Mine, 1996; Tojo et al, 1985; Hadgraft, 1980; Tu et al, 1979). This 
assumption has been chosen since most of the mathematical models that have 
been presented to describe the metabolic kinetics of drug during its diffusion 
through skin follow the first order kinetics as compared to Michaelis-Menten 
kinetics (Sugibayashi et al, 1999; Sugibayashi, et al 1996; Higuchi et al, 1983). 
Furthermore, Lipscomb and Poet (2008) concluded that in vivo drug 
concentration is usually below the Michaelis-Menten constant (Km) which leads 
to essentially consider the first order kinetics. In particular, the transdermal drug 
delivery has been reported to follow first order kinetics (Papa et al, 2009; 
Prodduturi et al 2009; Shakeel et al, 2008). 
(2) The distribution of the enzyme in the viable skin is assumed to be 
uniform (Boderke et al, 2000). Liu et al. (1990) proposed a theoretical diffusion 
model to examine the enzyme distribution. This model was based on the 
assumption of uniform enzyme distribution. The outcome of this study supports 
this assumption since the theoretical results agreed well with their experimental 
data. In another study, a mathematical absorption model with skin enzyme 
distribution has been developed (Hakima et al, 2006). The investigation shows a 
uniform enzyme distribution across skin. No significant differences have been 
observed between the uniform enzyme distribution model and non-uniform 
enzyme distribution model (Sugibayashi et al, 1999, Tojo et al, 1994). Therefore, 
this assumption is easily applicable to represent the drug diffusion profile across 
skin (Bando et al, 1996) which leads to a simplified theoretical model 
(Yamaguchi et al, 2006; Boderke et al, 2000). 
(3) For the simulations carried out using SKIN-CAD® (Biocoms systems, 
2006), the transport of verapamil across skin is described by one-dimensional 
diffusion model (Lv et al, 2006; Boderke et al, 2000). For the sake of simplicity, 
the one-dimensional diffusion has been assumed as this allows one to consider the 
effects of drug metabolism alone and not any other effects (e.g., dimensionality). 
Such assumption has been used in many mathematical models to describe the 
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transdermal drug delivery using microneedles (Lv et al, 2006; McAllister et al, 
2003). In particular, several studies have been obtained by carrying out 
simulations using SKIN-CAD® which assume one-dimensional method (Kimura 
and Tojo, 2007; Tojo and Hikima, 2007; Mori et al, 2003). The numerical results 
agreed well with the experimental data.  
(4) The diffusion coefficients are assumed to be constant in each layer 
(Boderke et al, 2000) although they may be different. The diffusion coefficient of 
verapamil has been shown to be three orders of magnitude less in the stratum 
corneum as compared to viable skin (Shah et al 1992a). It has been defined that 
the diffusion coefficient in the viable epidermis and dermis are of the same 
magnitude (Yamaguchi et al, 2008; Tojo, 2005). Therefore, it is acceptable to 
assume a constant value of the diffusion coefficient across the viable skin. 
(5) All the verapamil molecules are assumed to be taken up by the blood 
circulation (Al-Qallaf et al, 2007). This assumption has been previously explained 
in detail in previous publications e.g. Al-Qalaf et al (2009c) and Davidson et al 
(2008). 
(6) The body pharmacokinetics is defined to follow two-compartment 
model (Shah et al, 1992c; Anderson et al, 1982). The two-compartment model for 
verapamil has been chosen in consistency with previous studies which indicate 
this to be a better model as compared to the one-compartment model (Bertera et 
al, 2008; Syvanen et al, 2008). Ahmed et al. (1992) investigated the 
pharmacokinetic behaviour of verapamil for a range of models. Their results 
showed that the two-compartment model was the most appropriate model as 
compared to one-compartment and three-compartment models. 
(7) At x=h (Figure 1), the concentration of verapamil is defined to be zero 
(sink condition) (Al-Qallaf et al, 2007; Mori et al, 2003; Tojo, 2005). This 
assumption has also been previously explained in detail in Al-Qalaf et al (2009c) 
and Davidson et al (2008). 
(8) The back diffusion of verapamil in skin is ignored (Al-Qallaf et al, 
2007; Tojo, 2005; Shah et al, 1992c). This has been done since the diffusion 
coefficient of verapamil is small in the stratum corneum (Shah et al, 1992c). 
Therefore, it seems to be acceptable to ignore the back diffusion (Tojo, 2005). 
 
Governing equations characterizing the skin concentration 
 
The skin is represented by a bi-layer model which has two layers, stratum 
corneum and viable skin.  
In the case of neglecting the skin metabolism, the movement of verapamil 
across skin (Fig. 1) is based on Fick's second law as: 
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The initial verapamil concentration in skin is assumed to be zero. The boundary 
conditions used in this work for solving all the governing equations are: 
At the surface of the skin, the verapamil concentration is: 
 
)tt0(0xatCC as ≤<==      (3) 
 
Verapamil is assumed to be delivered at a constant rate, i.e., a constant skin 
surface concentration is maintained (Shah et al, 1992c). 
At the interface between stratum corneum and viable skin, the verapamil 
concentration is: 
 
)t0(hxatCKC scvsvs/scsc <==      (4) 
 
At the bottom of the skin epidermis, the concentration of verapamil is: 
 
)t0(hxat0C <==        (5) 
 
where C is the verapamil concentration, D is the diffusion coefficient and the 
subscripts s, sc and vs represent the skin surface, the stratum corneum and the 
viable skin, respectively, t is time, x is the distance in a given skin layer, Ksc/vs is 
the partition coefficient between the stratum corneum and the viable skin, ta is the 
duration of application of the drug delivery system, hsc is the stratum corneum 
thickness and h is the epidermis thickness (i.e., distance to blood vessel).  
As is well known, the metabolic reaction occurs in the viable skin and not 
in the stratum corneum (Tojo, 2005; Scheafer et al, 1982). Therefore, in the case 
of considering the metabolism the following equation is used instead of equation 
(2): 
 
Across the stratum corneum  
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where K is the first order metabolic reaction rate constant. 
As shown in Fig. 1, solid microneedles pierce the stratum corneum 
allowing verapamil to effectively bypass this barrier to diffusion. Therefore, the 
skin is represented by a mono-layer diffusion model in this work. The injected 
verapamil by microneedles diffuses across viable skin obeying Fick's second law 
until it reaches blood vessels (Al-Qallaf et al, 2007; Tojo, 2005; Boderke et al, 
2000). 
 
Governing equations characterizing the blood concentration 
 
The verapamil concentration in blood after imposing the transdermal drug 
delivery is given by the following two-compartmental pharmacokinetic model 
(Tojo, 20005); 
 
( ) tt21bb12eabb VCKVCKKSdt
dQ
dt
dC
V ++−⎟⎠
⎞⎜⎝
⎛=     (7) 
 
tt21bb12
t
t VCKVCKdt
dC
V −=       (8) 
 
where Ke is the elimination rate constant from the blood compartment, K12 and 
K21 are the transfer rate constants between compartments, dQ/dt is the penetration 
rate of verapamil through the skin, Sa is the surface area of the delivery system, 
Vb and Vt are the volumes of distribution in the blood and the tissue 
compartments, respectively, Cb and Ct are verapamil concentrations in the blood 
and the tissue compartments, respectively. The tissue compartment refers to the 
poorly perfuse non-fatty tissues such as muscle. 
 
Method of solution 
 
The governing equations with the initial and boundary conditions (1) – (8) have 
been implemented and solved using the software, SKIN-CAD® (Biocoms 
systems, 2006). The working principle of SKIN-CAD® has been explained in 
details elsewhere (Al-Qallaf et al, 2007; Tojo, 2005) and are not discussed here. 
In this work, we have predicted verapamil concentration in blood for the 
transdermal drug delivery with and without skin metabolism by using mono-layer 
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and bi-layer diffusion models in case of applying the microneedle arrays and the 
patch, respectively. 
The diffusion of coated verapamil has been modelled in 3D using the 
software, FEMLAB® (Comsol, 2005). The steady state diffusive flux of 
verapamil through the blood interface has been calculated by assuming that the 
concentration of verapamil on the needle surface is constant (Davidson et al, 
2008). This allows us to obtain the effective skin thickness by determining the 
flux from the simulations. The effective skin thickness (he) in case of applying 
microneedles is calculated as (Davidson et al, 2008): 
 
Jss
C
Dh avse =          (9) 
 
where Ca is verapamil concentration at the coated surface area of microneedles 
and Jss is the average steady-state flux through the blood interface. This is then 
used as an input parameter for SKIN-CAD®. This approach has been adopted 
following the work by Davidson et al (2008), which have previously shown that 
the effective skin thickness is influenced by the microneedle geometry. Equation 
(9) determines the effective path length of drug molecules once released from the 
microneedles. 
 
RESULTS AND DISCUSSION  
 
The impacts of the pharmacokinetic variables with skin metabolism have been 
studied by Shah et al. (1992c) However, this study was based on transdermal drug 
delivery by common patch on the top of stratum corneum. According to Shah et 
al. (1992c) there is a large difference in the pharmacokinetics variables of 
verapamil. Following this study we have evaluated the influence of 
pharmacokinetic variables on verapamil with the consideration of skin 
metabolism for both common patch and microneedle arrays. The values of the 
pharmacokinetics variables, which were used in our simulations, are shown in 
Table 1.  
Table 1. Pharmacokinetics variables of verapamil obtained from the references. 
   
Parameters 
 
References 
Vb×104 
(ml) 
Vt×104 
(ml) 
Ke × 10-4 
(s-1) 
K12 × 10-4 
(s-1) 
K21 × 10-4 
(s-1) 
Koike et al. (1979) 6.47 8.34 1.50 6.22 3.94 
Eichelbaum et al. 
(1981) 
27.39 13.14 0.79 2.12 2.78 
Anderson et al. 
(1982) 
2.63 5.18 1.58 2.19 1.11 
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To further quantify the influence of skin metabolism, we have 
hypothetically considered the patch at the top of viable epidermis with and 
without skin metabolism. We hypothesized this case since the metabolic process 
occurs in the viable epidermis as mentioned previously. 
The philosophy of this modelling strategy relies on comparing two 
hypothetical cases of transdermal delivery of verapamil using patch. This 
comparison is useful to evaluate the influence of skin metabolism and hence 
whether to consider the metabolic process in case of coated microneedles with 
verapamil. There seems to be no previous study Which considered the effect of 
metabolism while using microneedles. To achieve a logical result, those two cases 
have been simulated with a transdermal patch with the same input parameters. 
Based on this result, we have carried out simulations of transdermal delivery of 
verapamil using microneedles. The input parameters of those simulations are 
shown in Table 2. 
Table 2. Model parameters used in this work for analyzing the blood concentration of verapamil 
penetrated through the skin with and without skin metabolism for both common patch and 
microneedle arrays (Tojo, 1987; Shah et al, 1992c; Al-Qallaf et al, 2007). 
Patch Microneedles Parameters 
case onea case twob case onec case twod 
Duration for medication (calculation): tm (hour) 48 8 
Duration of application: td (hour) 24 4 
Surface area of  microneedle arrays/patch: Sa 
(cm2) 
80 2 
Thickness of stratum corneum: hsc (cm) 0.002 - - 
Distance to blood vessel: h (cm) 0.02 0.018 0.02 
Effective skin thickness: he (cm) - - 0.00819 0.00827 
Diffusion coefficient in stratum corneum: Dsc 
(cm2/s) 
7 ×10-11 - - 
Diffusion coefficient in viable skin: Dvs (cm2/s) 7 ×10-8 
Stratum corneum/viable skin partition coefficient: 
Ksc/vs (-) 
8 - - 
Volume of distribution: Vb(ml) variable 
Volume of distribution: Vt(ml) variable 
Elimination rate constant: Ke (s-1) variable 
Transfer rate constant: K12 (s-1) variable 
Transfer rate constant: K21 (s-1) variable 
Skin surface concentration: Cs (mg/ml) 344 43 43 
First order reaction metabolic rate constant: K (s-1) 5.61 ×  10-4 - 5.61 ×  10-4 
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Effect of skin metabolism in case of patch 
 
To examine the implications of skin metabolism in transdermal drug delivery of 
common patch, we have simulated cumulative amount permeated across the skin 
and blood concentration of verapamil with and without skin metabolism using 
model parameters as shown in both Table 1 and Table 2. As previously explained, 
this has been done by comparing one case where the transdermal patch is applied 
on the top of the stratum corneum (i.e., case one) with a hypothetical case where it 
is applied on the top of the viable epidermis without the stratum corneum (i.e., 
case two). 
Fig. 2 shows the cumulative amount of verapamil permeated per unit area 
of skin with and without metabolism when using the patch for case one. The 
cumulative amounts of verapamil permeated per unit area of skin with and 
without metabolism reached approximately 360 µg/cm2 and 830 µg/cm2, 
respectively, in 24 hours during the patch application. The calculated permeation 
flux without skin metabolism is approximately 2.3 times higher than that with 
skin metabolism during the patch application. The results seem to suggest that 
skin metabolism is an important factor for the transdermal delivery of verapamil. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2. The effect of skin metabolism on the cumulative amount of verapamil permeated into blood 
per unit area of skin following transdermal delivery using patch (i.e., on the top of the stratum 
corneum) for the input parameter adopted from Anderson et al(1982). 
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The effects of skin metabolism on the blood verapamil concentration using 
patch for case one are shown in Fig. 3. These simulations have been done using 
various literature values for pharmacokinetic parameters as shown in Table 1. The 
maximum verapamil concentration in blood (Cb,max) is different between the two 
cases (i.e., with and without metabolism). In case of considering skin metabolism, 
the maximum verapamil concentration in blood (Cb,max) for the pharmacokinetics 
parameters given by Anderson et al, (1982) Koike et al. (1979) and Eichelbaum et 
al. (1981) reached 0.09, 0.04 and 0.02 µg/ml, respectively. On the other hand, it 
reached 0.21, 0.09 and 0.04 µg/ml in case when skin metabolism is not 
considered. As expected, the results indicate that skin metabolism has a noticeable 
influence for the transdermal delivery of patch on the top of the stratum corneum. 
This result agrees well with the results presented by Shah et al. (1992c) 
qualitatively. The obtained results show that the skin metabolism is a relatively 
important factor for the process of transdermal delivery of verapamil if a patch is 
used (case one) since the difference in the maximum blood concentration is more 
than double as compared between both cases (i.e., with and without skin 
metabolism). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. The effects of various pharmacokinetic parameters with and without skin 
metabolism on the blood verapamil concentration following transdermal delivery using patch (i.e., 
on the top of the stratum corneum). 
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In contrast, Fig. 4 represents the cumulative amount of verapamil 
permeated per unit area of skin with and without skin metabolism for transdermal 
delivery by applying the patch on the top of the viable epidermis (case two). As 
explained previously, this case has been proposed to identify the importance of 
whether to consider the metabolic process in viable epidermis by comparing this 
case (i.e., case two) with the previous case (i.e., case one). The cumulative 
amounts of verapamil permeated per unit area of skin with and without 
metabolism reached approximately 9700 µg/cm2 and 14000 µg/cm2, respectively, 
in 24 hours. A less remarkable difference has been observed by comparing the 
simulated data with and without skin metabolism.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4. The effect of skin metabolism on the cumulative amount of verapamil permeated into blood 
per unit area of skin following transdermal delivery using patch (i.e., on the top of the viable 
epidermis) for the input parameter adopted from Anderson et al (1982) 
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compared with the case of transdermal delivery of verapamil by applying the 
patch on the top of stratum corneum (case one). The result of this case motivated 
us to further study the influence of skin metabolism during the injection of 
microneedles as discussed below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5. The effects of various pharmacokinetic parameters with and without skin metabolism on the 
blood verapamil concentration following transdermal delivery using patch (i.e., on the top of the 
viable epidermis). 
 
Effect of skin metabolism in case of microneedle systems 
 
Motivated with the previous results and to further study the skin metabolism 
effect, we have carried out simulations of transdermal delivery of verapamil using 
microneedle arrays with and without considering skin metabolism of the 
microneedle model as shown in Fig. 6.  
In case of not considering the skin metabolism effects, equation (2) has 
been used to describe verapamil transport across skin. On the other hand, in case 
of considering the skin metabolism effects, equation (6) has been used. Then the 
average flux of both cases has been determined by using FEMLAB® as discussed 
previously in section 2.2. The effective skin thickness (he) of transdermal delivery 
of verapamil using microneedles with and without skin metabolism has been 
calculated according to equation (9) for the parameters shown in Table 2. The 
utility of using the effective skin thickness has been previously explained in 
section 2.2. This has been used as an input parameter to calculate the verapamil 
concentration in blood by using SKIN-CAD®. No significant difference has been 
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observed in the effective skin thickness for both cases (i.e., with and without skin 
metabolism). This similarity appears because the effective skin thickness mainly 
depends on the flux at the blood interface which was almost the same for both 
cases since that microneedle reach much nearer to the blood interface where the 
drugs have only minimal contact with the dermal enzyme (Sugibayashi et al, 
1996; Higuch et al , 1983). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6. Schematic diagram of a microneedle model used in this work (i.e., the dotted area represents 
the surface area coated with verapamil).  
 
Figure 7 shows the cumulative amount permeated per unit area of skin for 
verapamil with and without metabolism. The cumulative amounts of verapamil 
permeated per unit area of skin with and without metabolism reached 
approximately 4900 µg/cm2 and 5400 µg/cm2, respectively. These figures also 
show that the differences between both cases (i.e., with and without skin 
metabolism) are lower as compared with the previous cases (i.e. case one and 
two). This result is consistent with our claim to not consider skin metabolism 
when designing microneedle arrays.  
 The verapamil concentration in blood starts to reduce after four hours as 
the duration of application is 4 hours as shown in Figure 8. In all cases, 
insignificant differences have been observed between both cases (i.e., with and 
without skin metabolism) (6-9%) when compared to case one (>50%). This is 
because the maximum verapamil concentration in blood (Cb,max) in both cases 
(i.e., with and without skin metabolism) for the pharmacokinetic parameters given 
by Anderson et al (1982), Koike et al (1979). and Eichelbaum et al (1981). 
reached  approximately  0.1  µg/ml,  0.04  µg/ml  and  0.01   µg/ml,   respectively. 
Altogether, the obtained results show that the skin metabolism is a relatively weak 
function of the process of transdermal delivery of verapamil if microneedle is 
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used since the difference in both the maximum blood concentration and 
cumulative amount of verapamil permeated into blood per unit area of skin are 
almost the same as compared between both cases (i.e., with and without skin 
metabolism). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.7. The effect of skin metabolism on the cumulative amount of verapamil permeated into blood 
per unit area of skin following transdermal delivery using microneedle arrays for the input 
parameter adopted from Anderson et al (1982). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.8. The effect of various pharmacokinetics parameters with and without skin metabolism on the 
blood verapamil concentration following transdermal delivery using microneedle arrays. 
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To further achieve a better knowledge of the transdermal delivery of 
verapamil using microneedles, the distribution of verapamil across skin in 3D has 
been obtained as shown in Fig. 9. This figure shows the distribution of verapamil 
concentration across skin without metabolism. This simulation has been utilized 
to determine the effective skin thickness (he) in order to use this value as an input 
parameter for the previous simulations which mimic the transdermal delivery of 
verapamil using microneedles. However, the distribution of verapamil 
concentration across skin with metabolism has not been presented since the 
concentration profile of both cases (i.e., with and without metabolism) are almost 
the same as shown previously in Fig. 8. During the injection of microneedles, the 
drug molecules are assumed to move through an isotropic media which is 
consistent with many previous works (e.g., Davis, 2003). The detailed explanation 
of FEMLAB has been avoided in this paper due to brevity of the paper and since 
they were explained in our other work (Davidson et al., 2008; Al-Qallaf et al., 
2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.9. Distribution of verapamil across skin without metabolism in 3D of the microneedle model. 
(the length 135m refers to the penetrated length of the microneedle, i.e. the length of the 
microneedle that has inserted into the skin, due to the property of the skin, the full length of the 
microneedle will not insert. The length of microneedle is 160 µm and the upper 0.5μm length of 
the microneedle is the uncoated length of the microneedle that has inserted into the skin.  
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All together, our result implies that the degree of skin metabolism effect is 
common patch (case one) > common patch (case two) > microneedles. This result 
indicates that skin metabolism will greatly influence the transdermal delivery of 
verapamil in the skin including the diffusion barrier (i.e., stratum corneum) and 
will not influence so much when the diffusion barrier is bypassed and the 
diffusion path length of the viable epidermis decreases. This conclusion accords 
well with the results conducted by Boderke et al (2000). The results obtained from 
the group’s experiment indicated that skin metabolism is connected with 
epidermal residence time, and this influenced the effect of metabolism on 
transdermal drug delivery. It has been shown here that the path length is much 
less using microneedles as compared to when the patch is placed on the skin 
surface. Hence a shorter epidermal residence time, which justifies the results of 
the numerical simulation showing that the when using microneedles the effect of 
skin metabolism is almost eliminated. To sum up, the findings indicate that not 
only the transdermal delivery of verapamil using microneedles has been improved 
but also the influence of skin metabolism has been reduced as compared with the 
transdermal delivery using common patch. 
 
CONCLUSION 
 
In recent years, microneedle arrays have been shown as one of the most promising 
technologies to deliver drugs across skin. However, more evaluations are needed 
to identify its usage for a medical application. One of these issues that should be 
examined clearly is the implication of drug metabolism in the skin on drug 
delivery by the microneedles. In this work, verapamil has been used as a model 
drug to simulate the influence of skin metabolism for microneedles. The mono-
layer and bi-layer skin diffusion models have been used to allow us to determine 
the effects of skin metabolism for all the cases of transdermal delivery of 
verapamil. The simulated results suggested that verapamil metabolism in the skin 
had a lower effect on the blood concentration in case of the patch applied on the 
top of viable epidermis and consequently in case of microneedle systems. These 
also supported our previous assumption of not considering drug metabolism in the 
skin for the process of transdermal drug delivery using microneedles (Al-Qallaf 
and Das, 2009a; Al-Qallaf and Das, 2009b; Davidson et al, 2008; Al-Qallaf et al, 
2007). On the other hand, the skin metabolism should be considered for the 
transdermal delivery of verapamil by applying a patch on the top of the stratum 
corneum. This mathematical modelling could be useful to design the microneedle 
systems of the drug metabolized in the skin. 
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